The current PE ratio of CTKB cannot be calculated, as the latest EPS of -$0.05 is negative. The most recent PE ratio recorded for Cytek Biosciences was 0.0 in September 2024.
Over the last four years, the average PE ratio of Cytek Biosciences has been 316.2. Analyzing the last four years, CTKB's PE ratio reached its highest point in the Sep 2021 quarter at 1,070.5, with a price of $21.41 and an EPS of $0.02. The Mar 2024 quarter saw the lowest point at 0, with a price of $6.71 and an EPS of $11,194.83.
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | N/A | N/A | $6.49 | -$0.05 |
2023 | N/A | N/A | $9.12 | -$0.09 |
2022 | 510.5 | N/A | $10.21 | $0.02 |
2021 | N/A | N/A | $16.32 | $0 |
2020 | N/A | N/A | N/A | $0.11 |
2019 | N/A | N/A | N/A | -$0.8 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | N/A | N/A | $6.49 | -$0.05 |
Sep 2024 | 0 | N/A | $5.54 | $18,591.78 |
Jun 2024 | 0 | N/A | $5.58 | $11,194.78 |
Mar 2024 | 0 | N/A | $6.71 | $11,194.83 |
Dec 2023 | N/A | N/A | $9.12 | -$0.09 |
Sep 2023 | N/A | N/A | $5.52 | -$6,456.05 |
Jun 2023 | N/A | N/A | $8.54 | -$0.04 |
Mar 2023 | N/A | N/A | $9.19 | -$0.01 |
Dec 2022 | 510.5 | N/A | $10.21 | $0.02 |
Sep 2022 | N/A | N/A | $14.72 | -$0.01 |
Jun 2022 | N/A | N/A | $10.73 | -$0.02 |
Mar 2022 | N/A | N/A | $10.78 | -$0.02 |
Dec 2021 | N/A | N/A | $16.32 | $0 |
Sep 2021 | 1,070.5 | N/A | $21.41 | $0.02 |
Jun 2021 | N/A | N/A | N/A | $0.07 |
Stock name | PE ratio | Market cap |
---|---|---|
OBIO Orchestra BioMed Holdings Inc | N/A | $128.11M |
OM Outset Medical Inc | N/A | $38.81M |
CTKB Cytek Biosciences Inc | N/A | $480.37M |
The current price to earnings ratio of CTKB cannot be determined, as its EPS of -$0.05 is negative.
Over the last four years, the quarterly PE ratio reached its highest level at 1,070.5 in the Sep 2021 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.